- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Madrigal Pharmaceuticals Inc (MDGL)
Madrigal Pharmaceuticals Inc stock price live, this page displays NASDAQ MDGL stock exchange data. View the MDGL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Madrigal Pharmaceuticals Inc real time stock price chart below.
What Is the Madrigal Pharmaceuticals Inc Stock Price Today?
The Madrigal Pharmaceuticals Inc stock price today is 464.71.
What Is the Stock Symbol for Madrigal Pharmaceuticals Inc?
The stock symbol for Madrigal Pharmaceuticals Inc is "MDGL."
What Stock Exchange Does Madrigal Pharmaceuticals Inc Trade On?
Madrigal Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Madrigal Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Madrigal Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MDGL quote. (ISIN: US5588681057)
What Is the Madrigal Pharmaceuticals Inc Stock Price Today?
The Madrigal Pharmaceuticals Inc stock price today is 464.71.
What Is the Stock Symbol for Madrigal Pharmaceuticals Inc?
The stock symbol for Madrigal Pharmaceuticals Inc is "MDGL."
What Stock Exchange Does Madrigal Pharmaceuticals Inc Trade On?
Madrigal Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Madrigal Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Madrigal Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MDGL quote. (ISIN: US5588681057)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
458.07
482.99
52 wk Range
265.00
615.00
Earnings results expected in 3 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
458.07482.99
52 wk Range
265.00615.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MDGL Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
671.07
Upside
+44.41%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Madrigal Pharmaceuticals Inc Company Profile
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals Inc SWOT Analysis
Rezdiffra's Triumph | Madrigal's NASH drug exceeds expectations with strong sales and patient uptake, driving optimism among analysts and showcasing potential market dominance |
Clinical Edge | Explore Rezdiffra's promising results in treating compensated MASH cirrhotics, outperforming competitors and potentially tapping into a $7-11 billion U.S. market |
Financial Trajectory | Delve into Madrigal's impressive financial performance, with analysts projecting 276% revenue growth in FY2025 and price targets ranging from $400 to $470 |
Strategic Horizons | Learn about Madrigal's plans for European expansion and Rezdiffra's potential applications in liver fibrosis and atherogenic lipids, broadening its market reach |
Madrigal Pharmaceuticals Inc Earnings Call Summary for Q3/2025
- Madrigal Pharma reported Q3 2025 EPS of -5.08, missing forecasts by 157.87%, while revenue exceeded expectations at $287.3M (up 17.53%), causing shares to fall 1.56% to $405.
- Net sales grew 35% quarter-over-quarter with Rezdiffra adoption reaching 29,500 patients and 60-70% adherence rates, putting the company on track to annualize over $1B in sales.
- Increased expenses impacted earnings significantly, with R&D costs rising to $174M from $68.7M and SG&A expenses climbing to $209.1M from $107.6M year-over-year.
- The company maintains a strong cash position of $1.1B and projects continued sales growth in 2026, with European market expansion and potential F4C approval anticipated in 2027.
- CEO Bill Sibold emphasized long-term MASH market leadership as the strategic focus, despite competitive pressures from Novo's market entry and below 10% current market penetration.
Last Updated: 2025-11-04, 09:38 a/m
Read Full TranscriptCompare MDGL to Peers and Sector
Metrics to compare | MDGL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMDGLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −36.5x | −2.1x | −0.5x | |
PEG Ratio | −0.76 | 0.05 | 0.00 | |
Price/Book | 16.9x | 2.5x | 2.6x | |
Price / LTM Sales | 14.3x | 59.5x | 3.3x | |
Upside (Analyst Target) | 37.5% | 62.1% | 47.0% | |
Fair Value Upside | Unlock | 5.0% | 5.9% | Unlock |
Analyst Ratings
14 Buy
2 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 671.07
(+44.41% Upside)
Earnings
Latest Release
Nov 04, 2025
EPS / Forecast
-5.08 / -1.97
Revenue / Forecast
287.27M / 244.42M
People Also Watch
FAQ
What Is the Madrigal Pharma (MDGL) Stock Price Today?
The Madrigal Pharma stock price today is 464.71
What Stock Exchange Does Madrigal Pharma Trade On?
Madrigal Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Madrigal Pharma?
The stock symbol for Madrigal Pharma is "MDGL."
What Is the Madrigal Pharma Market Cap?
As of today, Madrigal Pharma market cap is 10.55B.
What Is Madrigal Pharma's Earnings Per Share (TTM)?
The Madrigal Pharma EPS (TTM) is -13.04.
When Is the Next Madrigal Pharma Earnings Date?
Madrigal Pharma will release its next earnings report on Feb 19, 2026.
From a Technical Analysis Perspective, Is MDGL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Madrigal Pharma Stock Split?
Madrigal Pharma has split 1 times.
How Many Employees Does Madrigal Pharma Have?
Madrigal Pharma has 528 employees.
What is the current trading status of Madrigal Pharma (MDGL)?
As of Feb 16, 2026, Madrigal Pharma (MDGL) is trading at a price of 464.71, with a previous close of 473.79. The stock has fluctuated within a day range of 458.07 to 482.99, while its 52-week range spans from 265.00 to 615.00.
What Is Madrigal Pharma (MDGL) Price Target According to Analysts?
The average 12-month price target for Madrigal Pharma is USD671.07, with a high estimate of USD964 and a low estimate of USD570. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +44.41% Upside potential.
What Is the MDGL After Hours Price?
MDGL's last after hours stock price is 468.94, the stock has decreased by 4.23, or 0.91%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.